Skip to main content
. Author manuscript; available in PMC: 2015 Sep 11.
Published in final edited form as: Cell Rep. 2014 Aug 28;8(5):1447–1460. doi: 10.1016/j.celrep.2014.07.058

Figure 6. Silencing DDX1 promotes ovarian tumor cell invasion in vitro and ovarian tumor progression in vivo.

Figure 6

(A) Knockdown of DDX1 promotes ovarian tumor cell invasion. Matrigel invasion assays were performed on control or DDX1-knockdown SKOV3 and IG10 cells. Average numbers of invasive cells per field of view (FOV) were presented (**p < 0.001) (B) Knockdown of DDX1 promotes IG10 syngeneic tumor growth. Control and DDX1-knockdown IG10 cells expressing firefly luciferase were injected intraperitoneally into female C57BL/6N mice. Shown are the representative luciferase images of ovarian tumors. (C) Quantification of tumor weights and tumor nodules in mice (n = 10 for each group). Error bar represents the mean ± SEM. (D) Representative images of tumor nodules and metastases in the mice carrying syngeneic ovarian tumors derived from control and DDX1-knockdown IG10 cells. Shown here are tumor mass in omentum of a control tumor (I) and tumor mass in omentum (II), perihepatic area (III), mesentery (IV), lymph nodes (V), and diaphragm (VI) of DDX1-knockdown tumors. (E) Frequency of metastases to distant sites (mesentery, omentum, diaphragm, perihepatic and other sites). Other sites include paraaortic lymph nodes, kidney, and ovary. (F) Levels of miR-200a/b and their targets ZEB1 and ZEB2 in control and DDX-silenced tumors. Error bars represents the mean ± SD. (G) Immunohistochemical analysis of ZEB1, E-Cadherin and Vimentin in control and DDX1-knockdown ovarian tumors. Scale bar: 30 μm. Relative levels of ZEB1, E-Cadherin and Vimentin are shown in the graph (See Materials and Methods for IHC score, * p < 0.05). Error bars represents the mean ± SD.